Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve‐month randomized, double‐blind, placebo‐controlled trial

Wiley - Tập 52 Số 1 - Trang 27-35 - 2005
Mark Quinn1, Philip G. Conaghan2, Philip O’Connor2, Zunaid Karim2, Adam Greenstein2, Klaus Machold2, Clare Brown2, Alexander Fraser2, Stephen Jarret2, Paul Emery3
1Academic Unit of Musculoskeletal Disease, First Floor, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK.
2Leeds General Infirmary, Leeds, UK
3Leeds Teaching Hospitals Trust, Academic Unit of Musculoskeletal Disease, First Floor, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK

Tóm tắt

AbstractObjectiveAnti–tumor necrosis factor α agents are among the most effective therapies for rheumatoid arthritis (RA). However, their optimal use is yet to be determined. This 12‐month double‐blind study attempted remission induction using standard therapy with or without infliximab in patients with early, poor‐prognosis RA. The primary end point was synovitis (measured by magnetic resonance imaging [MRI]). Clinical observations continued to 24 months.MethodsAll patients had fewer than 12 months of symptoms. Assessments included full metrologic evaluation, laboratory tests, radiographs, functional evaluation using the Health Assessment Questionnaire (HAQ), and quality of life measurement using the RA Quality of Life (RAQoL) questionnaire. MRI was performed at 0, 4, 14, and 54 weeks; MR images were scored blindly. Patients received methotrexate (MTX) and were randomized to receive either infliximab or placebo for 12 months.ResultsTwenty patients were recruited (mean age 52 years, mean symptom duration 6 months, mean C‐reactive protein level 42 mg/liter, and 65% rheumatoid factor positive). At 1 year, all MRI scores were significantly better, with no new erosions in the infliximab plus MTX group; a greater percentage of infliximab plus MTX–treated patients fulfilled the American College of Rheumatology (ACR) 50% and 70% improvement criteria (78% versus 40% in the placebo plus MTX group and 67% versus 30%, respectively) and had a greater functional benefit (P < 0.05 for all comparisons). Importantly, at 1 year after stopping induction therapy, response was sustained in 70% of the patients in the infliximab plus MTX group, with a median Disease Activity Score in 28 joints (DAS28) of 2.05 (remission range). At 2 years, there were no significant between‐group differences in the DAS28, ACR response, or radiographic scores, but differences in the HAQ and RAQoL scores were maintained (P < 0.05).ConclusionRemission induction with infliximab plus MTX provided a significant reduction in MRI evidence of synovitis and erosions at 1 year. At 2 years, functional and quality of life benefits were sustained, despite withdrawal of infliximab therapy. These data may have significant implications for the optimal use of expensive biologic therapies.

Từ khóa


Tài liệu tham khảo

10.1136/ard.54.12.944

10.1093/rheumatology/40.11.1211

Emery P, 1997, Prognosis in inflammatory arthritis: the value of HLA genotyping and oncological analogy, J Rheumatol, 24, 1436

10.1002/art.11156

Quinn MA, 2003, Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention, Clin Exp Rheumatol, 21, S154

10.1056/NEJM200011303432202

10.1056/NEJM200011303432201

10.1002/art.10308

10.1016/S0016-5085(99)70224-6

10.1016/S0140-6736(02)08215-6

10.1016/S0140-6736(00)02530-7

10.1056/NEJM199905063401804

10.1093/rheumatology/keg454

10.1002/art.10747

10.1002/1529-0131(199905)42:5<918::AID-ANR10>3.0.CO;2-2

10.1002/art.11076

10.1002/art.1780310302

10.1002/art.1780261107

10.1016/S0950-3579(96)80043-4

10.1002/art.1780380602

10.1002/art.1780380107

10.1093/rheumatology/36.8.878

10.1093/rheumatology/37.11.1157

Van Leeuwen MA, 1997, Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis: towards development of a decision support system, J Rheumatol, 24, 20

10.1002/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N

10.1002/1529-0131(200110)44:10<2242::AID-ART386>3.0.CO;2-F

10.1002/art.1780390412

Devlin J, 1997, The acute phase and function in early RA: CRP levels correlate with functional outcome, J Rheumatol, 24, 9

10.1016/S0140-6736(97)01300-7

10.1016/S0140-6736(98)08513-4

10.1016/S0016-5085(03)00382-2

Thông tin
Thông tin xuất bản

Wiley

Tập 52 Số 1

27-35

Thông tin tác giả